Although pharmaceuticals and pesticides are evaluated for toxicity at great cost, numerous anthropogenic compounds produced in sizable amounts and present in our everyday environment have not been tested for any toxicologic activity. The recent California Green Chemistry Report ([@b7-ehp-117-1867]) illustrates that far more chemicals are in common use than the ones tested for toxicity, and in most cases, there are few or no toxicity data for a large number of these chemicals. Novel international legislation, such as the Registration, Evaluation, Authorization and Restriction of Chemicals (REACH) program implemented in 2007 by the European Union ([@b14-ehp-117-1867]), requires that all chemicals used in the European Union at more than 1 metric ton/year/company be evaluated for their toxicity over the next decade. Ultimately, the European Union may develop an authorization system to control substances of very high concern and progressively replace them with suitable alternatives where economically and technically viable, unless there is an overall benefit for society of using the substance. The U.S. Environmental Protection Agency has several voluntary programs, including the High Production Volume Challenge Program ([@b47-ehp-117-1867]), that allow compiling of chemical toxicity and hazard information for selected chemicals. It is very likely that additional national and international legislation will be enacted that will require generation of toxicity data for most of the chemicals produced in sizable quantity.

For almost 200 years, laboratory animal testing has been the major tool of toxicologists ([@b16-ehp-117-1867]). However, such tests have the disadvantages of being both time-consuming and very costly because they require use of large number of animals, and they are not always predictive of human risk. For the implementation of REACH, [@b42-ehp-117-1867] estimated that tens of million of animals will be used at a cost of several hundred thousand dollars per compound, making it very challenging to use experimental animals to complete analysis of the toxicologic effects of many chemicals in a reasonable time frame. Accordingly, there is a need for accurate toxicologic evaluation of xenobiotics to be faster and more cost-effective. Progress in molecular biology, biotechnology, and other fields have paved the way for toxicity testing to be quicker, less expensive, and more directly relevant to human exposures ([@b18-ehp-117-1867]). Although it is certain that *in vitro* assays cannot yet replace animal testing ([@b46-ehp-117-1867]), they may provide essential information that can prioritize and dramatically reduce the use of animal testing assays ([@b44-ehp-117-1867]). However, when considering the prospect of screening tens of thousands of chemicals against hundreds of *in vitro* assays, several important questions need to be answered. Can enzyme- or cell-based bioassays yield useful toxicologic information? Furthermore, can these assays be conducted in a high-throughput and reliable fashion, allowing the rapid screening of thousands of compounds for biological and toxicologic activities?

As part of the University of California--Davis Superfund Basic Research Program, whose aim is to identify biomarkers of exposure and effects of toxic substances, we have developed a library of techniques, including numerous enzyme- and cell-based screening assays ([@b1-ehp-117-1867]; [@b17-ehp-117-1867]; [@b20-ehp-117-1867]; [@b22-ehp-117-1867]; [@b24-ehp-117-1867]; [@b32-ehp-117-1867]; [@b39-ehp-117-1867]; [@b43-ehp-117-1867]). Although such assays are routinely used to find novel small chemical inhibitors in the pharmaceutical industry, we tested whether such mechanistically based screening assays can be used to rapidly provide information on the potential for compounds to produce specific biological toxic effects that would identify those requiring further in-depth study. More specifically, we tested whether these assays could be adapted for high-throughput screening (HTS). We selected a small (176 compounds) and structurally very diverse library from among commonly encountered environmental chemicals. We report the results of screening this library with nine enzyme-based and five receptor-based bioassays. These assays were selected because the proteins involved were shown to interact with xenobiotics, and because the *in vitro* effects of these xenobiotics could be related to the *in vivo* activity of these proteins and health effects.

Materials and Methods
=====================

A more detailed account of the materials and methods used is given in the Supplemental Materials, (doi:10.1289/ehp.0900834.S1 via <http://dx.doi.org/>).

Chemicals
---------

Most chemicals used in the library were from commercial sources. Chemicals were at least 95% pure and used without further purification.

Environmental chemicals library
-------------------------------

The library was prepared in 2-mL deep-well polypropylene 96-well assay plates. Every compound was dissolved at 10 mM in dimethyl sulfoxide (DMSO). Only compounds totally soluble at 10 mM in DMSO were included in the library. In each plate, the wells in the first column contained only DMSO to serve as controls. In the remainder of the plate, we dispensed one compound per well, with 88 compounds total per plate. We created two plates for a total of 176 compounds. A detailed description of the chemical contents in each plate is presented in the Supplemental Materials, Tables 1 and 2 (doi:10.1289/ehp.0900834.S1). The sealed plates were stored at −20°C until use. Upon use, the plates were diluted to the appropriate concentration using a robotic pipetting station.

Enzyme preparations
-------------------

Recombinant human soluble epoxide hydrolase (sEH) was produced in a baculovirus expression system ([@b2-ehp-117-1867]) and purified by affinity chromatography ([@b49-ehp-117-1867]). Recombinant human carboxylesterases CES1, CES2, and CES3; fatty acid amide hydrolase (FAAH); and paraoxonase 2 (PON2) were expressed in baculovirus-insect cells as previously described ([@b22-ehp-117-1867]; [@b34-ehp-117-1867]). The CESs were partially purified as previously described ([@b34-ehp-117-1867]), whereas microsomal preparations were used for FAAH and PON2 ([@b22-ehp-117-1867]). Human liver cytosol and microsome extracts were obtained from BD Biosciences (San Jose, CA). Protein concentration was quantified using the Pierce BCA (bicinchoninic acid) assay (Pierce, Rockford, IL) using bovine serum albumin (BSA) as the calibrating standard.

Enzyme assays
-------------

Although the conditions for each enzyme assay were different (for details, see [Table 1](#t1-ehp-117-1867){ref-type="table"}), the enzymatic assays were all run in a similar format. Enzymes were used at a concentration that results in linear generation of product with increasing time and protein concentration, as well as yielding a signal that was 3--20 times greater than the background. BSA (0.1 mg/mL final concentration) was added to all buffers just before use to reduce nonspecific inhibition ([@b29-ehp-117-1867]). For glutathione *S*-transferase (GST) activities, the buffer was supplemented with 5 mM glutathione. For all the enzyme assays, we tested the compounds at final concentrations of 0.1 and 1 μM.

Kinetic assay conditions
------------------------

The dissociation constant of triclosan for CES1 was determined following the method described by [@b12-ehp-117-1867] for competitive tight binding inhibitors, using cyano(6-methoxy-2-naphthyl)methyl acetate (CMNA) as the substrate ([@b43-ehp-117-1867]). Inhibitor concentrations between 0 and 1,000 nM were incubated in triplicate for 5 min in sodium phosphate buffer (pH 7.4) at 30°C with 200 μL of the enzyme solution. Substrate at a final concentration of 5--100 μM was then added. Velocity of the reaction was measured as described above. For each substrate concentration, plots of velocity as a function of inhibitor concentration allow the determination of an apparent inhibition constant (K~Iapp~). The plot of K~Iapp~ as a function of the substrate concentration allows the determination of K~I~ when the substrate concentration is zero. Results were expressed as the mean ± SD of three separate K~I~ measurements.

Cell-based bioassays
--------------------

[Table 2](#t2-ehp-117-1867){ref-type="table"} presents an overview of the different cell-based bioassays used. For all test compounds, agonist activity in the aryl hydrocarbon receptor (AhR), androgen receptor (AR), and estrogen receptor (ER) assays was determined in the AhR, AR, and ER CALUX (chemically activated luciferase expression) bioassays, respectively. All three CALUX bioassays make use of different cell lines (H1L6.1c2, T47D-AR--positive, and BG1Luc4E2/ER-α--positive, respectively) that contain a stably transfected luciferase gene under the transcriptional control of DNA response elements for the activated AhR, AR, and ER, respectively ([@b17-ehp-117-1867]; [@b20-ehp-117-1867]; [@b39-ehp-117-1867]). Activation of the receptor signaling pathway was determined by quantifying the luciferase activity in the absence or presence of a known agonist \[2,3,7,8-tetrachlorodibenzo-*p*-dioxin (TCDD), 17β-estradiol (E~2~), or dihydrotestosterone (DHT)\]. Results were expressed relative to luciferase activity maximally induced by a reference compound (1 nM TCDD for AhR, 10 nM DHT for AR, 1 nM E~2~ for ER). For these assays, the primary screening of the library was done at 10 μM. Membranes enriched in ryanodine receptors (RyRs) were obtained either from adult rabbit skeletal muscle, a pure type 1 ryanodine receptor (RyR1) source ([@b40-ehp-117-1867]), or from cardiac ventricular tissue, a pure type 2 ryanodine receptor (RyR2) source ([@b36-ehp-117-1867]). Activation or inhibition of the receptors was measured by quantifying the ability of the tested compound at 5 μM to enhance or inhibit the basal binding of \[^3^H\]Ry (2 nM) in the presence of 20 μM CaCl~2~. After a 3-hr incubation at 37°C, the reactions were quenched by filtration through GF/B-grade glass fiber filters and washed twice with ice-cold harvest buffer containing 20 μM CaCl~2~. \[^3^H\]Ry binding was quantified by measuring the radioactivity collected on the filter.

Selection of positive hits and counterscreening
-----------------------------------------------

For the enzyme assays, a compound was selected as a positive hit if it resulted in \> 50% inhibition at the lower concentration (100 nM) and if it resulted in more than 60% inhibition at the higher concentration (1 μM). For the cell-based assays, we selected compounds that significantly (*t*-test and *F*-test, *p* \< 0.01) induced the receptor activation of gene expression. For counterscreening, fresh solutions of all positive compounds were prepared in DMSO. For the enzyme assays, the concentration of each compound that inhibited 50% of the enzyme activity (IC~50~) was determined by measuring enzyme activities in the absence and presence of increasing concentrations of inhibitor (ranging from 0.5 to 10,000 nM). IC~50~ values were calculated by nonlinear regression of at least five data points using SigmaPlot, version 9.01 (Systat Software Inc., Chicago, IL). Results are provided as the mean ± SD of at least three separate measurements. Similarly, half-maximal effective concentration (EC~50~) values for agonists of the AhR and ER bioassays were determined, and the results are presented as the mean of triplicate analysis. For the assay of \[^3^H\]Ry binding to RyR1 or RyR2, the influence of 5 μM of each compound was screened for its ability to either enhance or inhibit specific radioligand binding more than twice the baseline (defined as the level of \[^3^H\] Ry-specific binding in the presence of DMSO alone). Therefore, a positive hit on RyR1 or RyR2 was defined as ≥ 200% of control binding for activators, or ≤ 50% of control for inhibitors.

Results and Discussion
======================

Assays characteristics and positive hits selection
--------------------------------------------------

Using results from the blank and full activity controls, we evaluated the suitability of each assay for use as HTS assays. We therefore calculated the signal-to-background ratio (S/B), the signal-to-noise ratio (S/N), and the *Z*′ factor as defined by [@b51-ehp-117-1867]. As shown in [Table 3](#t3-ehp-117-1867){ref-type="table"}, we found that S/B ratios varied from 2.5 to \> 150, with the lowest value for the absorbance-based assay (GSTs) and the highest for the radioactive-based assays (RyRs). Similarly, the S/N ratios varied greatly, with a lower value for the absorbance assay and the higher values for the radioactive-based assays. In general, the enzyme-based assays yielded higher *Z*′ factors than did the cell-based bioassays. For the enzyme assays, *Z*′ values were \> 0.7, indicating very good and reliable assays that are easily suitable for HTS assays. Although the cell-based assays yielded lower *Z*′ factors, the values were still \> 0.5, suggesting that the discrimination is adequate and that these assays could be used in HTS assays. Nevertheless, for the RyR assays, a larger separation band and higher *Z*′ factor could be obtained by reducing the SD of the signal, which was around 20%.

The aims of the primary screening were to identify all possible positive hits and to ensure there were no false negatives. Thus, for the primary screening of the library, we tested the xenobiotics at relative high concentrations (0.1 and 1 μM for the enzymes, and 5 and 10 μM for the receptors), which should be far higher than blood concentrations resulting from exposure. Thus, it is unlikely that compounds found negative in the primary screening will be false negative and affect the tested proteins *in vivo*. Generally, testing higher concentrations result in solubility problems for an increasing proportion of compounds. Based on our definition of positive hits (described above), for the 14 assays we obtained a total of 69 positive results ([Table 3](#t3-ehp-117-1867){ref-type="table"}), which represent on average five positive hits per assay, or 3% of the library. For FAAH, GST, and AR bioassays, we obtained no hits from the screening. There were twice as many positive hits from chemicals in plate II (42) than from those in plate I (27) \[see Supplemental Material, Figure 1 (doi:10.1289/ehp.0900834.S1)\]. The latter plate contained numerous triazine herbicides that did not result in any significant inhibition in any assay. Although three compounds \[carbophenothion, triclosan, and triphenyl phosphate (TPP)\] gave positive results with three enzymes or more, all the target enzymes were esterases.

Even if the assays are of high quality, as defined by their S/B, S/N, and *Z*′ factors (described above), false positives are bound to happen as they are dependent on the compounds tested and not on the assays. False positives are mostly due to nonspecific binding, alteration of the reporting signal (quenching of the fluorescence signal, cytotoxicity to the cells, etc.), and chemical modifications during storage of the chemicals. The purpose of the counterscreening is to eliminate false positives. To reduce nonspecific inhibition, BSA (0.1 mg/mL final concentration) was added to all buffers just before use ([@b29-ehp-117-1867]). To eliminate alteration of the reporting signal, we tested the ability of each positive hit to quench the fluorescent or luminescent signal as well as its possible cytotoxic effect. Unfortunately, it is not possible to run such controls in the primary screen format. Finally, to reduce false positives resulting from some chemical modification upon storage, we prepared a fresh solution of each positive hit just before counterscreening. Out of the 69 positive hits initially found in the library screening, individual counterscreening analysis confirmed that 39 of them are effectively positive hits (see definition above), indicating an approximately 40% false-positive rate for the primary screening. This relatively high number of false positives reflects the high concentrations used for the primary screening. A lower screening concentration will have a lower number of false positives but will significantly increase the chance of false negatives, which is not desirable. Overall, using this two-step screening method, we found that 98% of the compounds tested have no effects on the tested assays.

Individual enzymes and receptors results
----------------------------------------

For all the positive hits selected from the library screening, we determined their individual inhibition or induction potency (IC~50~ or EC~50~) toward an enzyme or a receptor ([Table 4](#t4-ehp-117-1867){ref-type="table"}), except for the RyR assays, which are the subject of a forthcoming study. As expected, we found that sEH was strongly inhibited by two urea-containing compounds, which are a well-established class of sEH inhibitors ([@b30-ehp-117-1867]): siduron and triclocarban \[trichlorocarbanilide (TCC)\]. Although siduron uses are limited, TCC is present in numerous personal care products ([@b1-ehp-117-1867]), suggesting a large exposure risk. Animal models have shown that inhibition of the sEH affects human health by altering homeostasis, blood pressure, inflammation, and pain ([@b31-ehp-117-1867]).

Inhibition of the CESs by organophosphate xenobiotics ([Table 4](#t4-ehp-117-1867){ref-type="table"}), such as carbophenothion, parathion, phosdrin, and TPP, was expected, because such compounds are common mechanistic suicide inhibitors of serine hydrolases after activation to the oxon form ([@b8-ehp-117-1867]). Because the CESs are only slowly reactivated, there is thus a cumulative risk. Although many organophosphate insecticides have been or are being phased out around the world, TPP continues to be used both as a plasticizer and a fire retardant in electronic components. Burning or leaching of TPP from electronic waste could result in its presence in water ([@b35-ehp-117-1867]). Given the role of CES in the metabolism of ester- and amide-containing xenobiotics ([@b41-ehp-117-1867]), CES inhibition could lead to increased toxicity of xenobiotics. In general, CES inhibitors contain a carbonyl that reacts with the active-site serine to form a tetrahedral intermediate ([@b21-ehp-117-1867]). Thus, the inhibition of CES1 and CES2 by triclosan, present in numerous personal care products ([@b1-ehp-117-1867]), was unexpected. To understand the mechanism of action of triclosan, we determined its kinetic constant \[see Supplemental Material, Figure 2 (doi:10.1289/ehp.0900834.S1)\]. We found that triclosan inhibits CES1 by a competitive mechanism and a K~I~ of 105 ± 5 nM. Although not the most potent of known CES1 inhibitors, triclosan represents a lead compound for a new class of esterase inhibitors.

PON2 was first identified as an enzyme that protects humans from environmental poisoning by organophosphate derivatives ([@b23-ehp-117-1867]); thus, one could expect apparent inhibition of this enzyme by organophosphates as we observed ([Table 4](#t4-ehp-117-1867){ref-type="table"}). For carbophenothion and tributyl phosphotrithioite, this is likely due to traces of oxon impurities. Interestingly, we found that, in addition to CES1 and CES2, TPP can also significantly reduce PON2 activity. Inhibition of PON2 could lead to increased atherosclerosis and cardiovascular risk ([@b23-ehp-117-1867]). Taken together, exposure to TPP could affect human health through various modes of action.

For the two cytochrome P450 (CYP450) activities tested, significant inhibition was observed only for CYP450 2C9 ([Table 4](#t4-ehp-117-1867){ref-type="table"}). 2-Methylheptyl-4,6-dinitrophenyl crotonate, the active ingredient in the fungicide dinocap, was the only very potent inhibitor of this CYP450 found. Interestingly CYP450 2C9 is involved in the production of antiinflammatory and antihypertensive epoxyeicosatrienoic acids from arachidonic acid; thus, inhibition of this CYP450 could lead to increased cardiovascular risk ([@b31-ehp-117-1867]).

Screening results for the three nuclear receptor signaling pathways (AhR, ER, and AR) identified seven compounds with significant agonist activity: two for AhR, five for ER, and none for AR. Interestingly, even given the promiscuity of AhR ligand binding ([@b10-ehp-117-1867]; [@b11-ehp-117-1867]), only two fungicide chemicals, 2-(4-chlorophenyl)-benzothiazole (CPB) and dichlone, induced AhR-dependent gene expression, and they were relatively weak inducers. CPB and dichlone EC~50~ values for induction ([Table 4](#t4-ehp-117-1867){ref-type="table"}) were approximately 5 × 10^5^-fold less potent than the prototypical AhR agonist TCDD. Although dichlone is a newly identified AhR agonist, CPB was previously reported to induce AhR-dependent expression of cytochrome CYP450 1A1 in human and mouse cell lines ([@b25-ehp-117-1867]). As expected, we found that ER signal transcription was activated by *o*,*p*′-DDT (dichlorodiphenyltrichloroethane) and its metabolites *o*,*p*′-DDE (dichlorodiphenyldichloroethylene) and *o*,*p*′-DDD (dichlorodiphenyldichloroethane) ([@b9-ehp-117-1867]; [@b39-ehp-117-1867]), and our screening identified *o*,*p*′-DDE and *o*,*p*′-DDD as activators also (*o*,*p*′-DDT was not present in the screened library). In our system, the EC~50~ for induction by *o*,*p*′-DDE and *o*,*p*′-DDD was approximately 10^5^-fold less potent than that of E~2~ ([@b39-ehp-117-1867]). Similarly, bisphenol A (BPA) and lindane have also been previously identified as ER agonists ([@b5-ehp-117-1867]; [@b28-ehp-117-1867]; [@b45-ehp-117-1867]; [@b48-ehp-117-1867]), although lindane has been suggested to activate ER-dependent gene expression through a nonclassical mechanism ([@b45-ehp-117-1867]). BPA was the most potent ER agonist identified, only 3,000-fold less potent than E~2~, whereas lindane was the weakest. Taken together, the relatively low potency of these agonists coupled with existing controversies regarding exposure and health risks associated with BPA and other endocrine-disrupting chemicals ([@b48-ehp-117-1867]) suggests that the adverse effects of these chemicals remain to be determined.

Our primary screen revealed that numerous compounds affected the RyRs, such as triclosan, which we previously showed to increase \[^3^H\]Ry binding to RyR1 ([@b1-ehp-117-1867]). For counterscreening, we concentrated on the 12 chemicals that produced the most significant RyR effect ([Figure 1](#f1-ehp-117-1867){ref-type="fig"}). Overall, the profiles for both receptors are similar, with the profile of RyR2 being more attenuated than that for RyR1. For the latter protein, we found eight compounds (at 5 μM) that significantly affected the binding of \[^3^H\]Ry: five of them inhibited the binding, and three increased it. For RyR2, we found four compounds that significantly inhibited this receptor. For both receptors, the largest effect was observed for chloranil (IC~50~ \< 1.0 μM) and dichlone (IC~50~ \< 1.0 μM), which both contain in their structure a 2,3-dichloro-1,4-quinone. These results are consistent with our previously published work showing that naphthoquinones and benzoquinones are capable of selectively modifying RyR1 channels in a time- and concentration-dependent manner ([@b15-ehp-117-1867]). Interestingly, we found that \[^3^H\]Ry binding to RyR1 was increased almost 3-fold by chlorpyriphos and *o*,*p*′-DDE. Counterscreening results suggested that baythroid, α-cypermethrin, deltamethrin, and *N*-cyclohexyl-2-benzothiazyl sulfonamide have no significant effect on either RyR at 5 μM. Obtaining a compound that interacts specifically with only one of the RyRs or has opposing effects on both proteins will be scientifically very important. The deltamethrin scaffold could be a lead toward such compounds, because deltamethrin seemed to have opposing effects on both RyRs. RyR1 and RyR2 are major components of skeletal and cardiac muscle excitation contraction coupling, and several heritable mutations in these proteins have been associated with myogenic disorders ([@b3-ehp-117-1867]). In addition, RyR1 and RyR2 are the major isoforms expressed in neurons and are responsible for producing temporally and spatially defined Ca^2+^ signals important for neuronal growth and plasticity ([@b4-ehp-117-1867]). Deregulation of RyR function and expression contributes to alterations in activity-dependent dendritic growth and plasticity ([@b26-ehp-117-1867]; [@b38-ehp-117-1867]; [@b50-ehp-117-1867]) and the balance of excitatory and inhibitory neurotransmission in the hippocampus CA1 region ([@b27-ehp-117-1867]). Thus, exposure to the RyR channel activators and inhibitors identified here could trigger adverse contractile responses in muscle cells and affect proper brain development, especially in susceptible individuals.

Conclusion
==========

The HTS method described herein allowed the elimination of 98% of the compounds as negative hits. Furthermore, we were able to correctly identify compounds that were previously shown to inhibit or induce a particular enzymes or receptor; however, we also discovered new effects of some xenobiotics. For example, the inhibition of CES1 and CES2 by triclosan was totally unexpected, as was the inhibition of the RyRs by chloranil and dichlone. These *in vitro* results raise significant biological/toxicologic questions and further *in vivo* studies are necessary before drawing any conclusions on the health risks associated with any of these compounds by these specific mechanisms. Overall, our study shows the feasibility of using combined HTS assays as an approach toward obtaining toxicologic data on the many thousands of anthropogenic compounds for which there is little if any information. Furthermore, the HTS assays were very useful for quickly identifying compounds of potential risk for further studies, thus concentrating resources on the potentially most significant chemicals.

The National Library of Medicine has developed the infrastructure to screen compounds on possible pharmacologic leads and to report the data in an easily accessible publically available format; this is part of the National Institutes of Health Molecular Libraries Roadmap initiative. The results for the screening of sEH in this system are available online ([@b33-ehp-117-1867]); the AhR CALUX bioassay is currently used in the same program. One useful rapid approach would be for investigators or the National Institute of Environmental Health Sciences to propose toxicologically relevant assays and also provide environmentally or industrially important compounds to the system.
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Supplemental Material is available online (doi:10.1289/ehp.0900834.S1 via <http://dx.doi.org/>).

![Effect of 5 μM of ferbam (P51), maneb (P52), tetramethyl-thiuram disulfide (P54), pirimiphos-methyl (P56), chlorpyrifos (P60), *o*,*p*′-DDE (P86), chloranil (P98), dichlone (P99), baythroid (P116), α-cypermethrin (P117), deltamethrin (P123), and *N*-cyclohexyl-2-benzothiazyl sulfonamide (P172) on the binding of \[^3^H\]Ry to the RyRs compared with DMSO control. A positive value indicates that the binding of \[^3^H\]Ry was increased; a negative value indicates that the binding of \[^3^H\]Ry was inhibited. The dashed lines at 1 and --1 are reference lines for no change in the binding of \[^3^H\]Ry to the receptors.\
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###### 

Conditions for human enzyme-based bioassays.

  Enzyme               Preparation used                        Substrate     Concentration (μM)   Buffer                       End point measured     Reference
  -------------------- --------------------------------------- ------------- -------------------- ---------------------------- ---------------------- ---------------------
  sEH                  Recombinant purified enzyme             CMNPC         5                    Bis-Tris/HCl pH 7.0, 25 mM   Fluorescence kinetic   [@b24-ehp-117-1867]
  CES1                 Recombinant partially purified enzyme   CMNA          50                   Na~2~PO~4~ pH 7.4, 0.1 M     Fluorescence kinetic   [@b43-ehp-117-1867]
  CES2                 Recombinant partially purified enzyme   CMNA          50                   Na~2~PO~4~ pH 7.4, 0.1 M     Fluorescence kinetic   [@b43-ehp-117-1867]
  CES3                 Recombinant partially purified enzyme   CMNA          50                   Na~2~PO~4~ pH 7.4, 0.1 M     Fluorescence kinetic   [@b43-ehp-117-1867]
  FAAH                 Recombinant microsomes                  Octanoyl-MP   50                   Na~2~PO~4~ pH 8.0, 0.1 M     Fluorescence kinetic   [@b22-ehp-117-1867]
  PON2                 Recombinant microsomes                  CMNA          50                   Na~2~PO~4~ pH 7.4, 0.1 M     Fluorescence kinetic   [@b43-ehp-117-1867]
  GSTs                 Pooled human liver cytosol              CDNB          1,000                K~2~PO~4~ pH 6.5, 0.1 M      Absorbance kinetic     [@b19-ehp-117-1867]
  CYP450 1A2 and 2C6   Pooled human liver microsomes           EROD          25                   K~2~PO~4~ pH 7.4, 0.1 M      Fluorescence kinetic   [@b13-ehp-117-1867]
  CYP450 2C9           Pooled human liver microsomes           Luciferin H   50                   K~2~PO~4~ pH 7.4, 0.1 M      Luminescence           [@b6-ehp-117-1867]

Abbreviations: CDNB, 1-chloro-2,4-dinitrobenzene; CMNA, cyano(6-methoxy-2-naphthyl)methyl actetate; CMNPC, cyano(6-methoxy-naphthalen-2-yl)methyl *trans*-\[3-phenyloxiran-2-yl)methyl\] carbonate; EROD, ethoxyresorufin; Octanoyl-MP, *N*-(6-methoxypyridin-3-yl) octanamide.

###### 

Conditions for cell-based bioassays.

  Human receptor              Acronym   Preparation used               Substrate    End point measured   Reference
  --------------------------- --------- ------------------------------ ------------ -------------------- ---------------------
  Aryl hydrocarbon receptor   AhR       Recombinant cells              Luciferin    Luminescence         [@b20-ehp-117-1867]
  Androgen receptor           AR        Recombinant cells              Luciferin    Luminescence         [@b39-ehp-117-1867]
  Estrogen receptor           ER        Recombinant cells              Luciferin    Luminescence         [@b39-ehp-117-1867]
  Ryanodine receptor 1        RyR1      Skeletal muscle membranes      \[^3^H\]Ry   Radioactivity        [@b37-ehp-117-1867]
  Ryanodine receptor 2        RyR2      Ventricular muscle membranes   \[^3^H\]Ry   Radioactivity        [@b36-ehp-117-1867]

###### 

Characteristics and positive primary screen results for enzyme- and cell-based bioassays.

                        Assay characteristics   No. of positive results                     
  --------------------- ----------------------- ------------------------- ------------ ---- -----
  Enzyme                                                                                    
   sEH                  4.0 ± 0.1               38 ± 8                    0.8 ± 0.1    2    2
   CES1                 11 ± 3                  19 ± 2                    0.8 ± 0.1    4    2
   CES2                 9.2 ± 0.9               106 ± 33                  0.8 ± 0.1    4    3
   CES3                 6.1 ± 0.7               28 ± 7                    0.7 ± 0.1    7    4
   FAAH                 150 ± 10                35 ± 5                    0.8 ± 0.1    0    ---
   PON2                 18 ± 2                  134 ± 31                  0.8 ± 0.04   4    3
   GSTs                 2.4 ± 0.5               28 ± 9                    0.7 ± 0.05   0    ---
   CYP450 1A2 and 2C6   13 ± 5                  48 ± 10                   0.7 ± 0.1    1    0
   CYP450 2C9           19 ± 4                  79 ± 18                   0.7 ± 0.05   12   7
  Receptor                                                                                  
   AhR                  32 ± 1                  410 ± 30                  0.6 ± 0.2    3    2
   AR                   18 ± 2                  180 ± 70                  0.7 ± 0.1    0    ---
   ER                   5 ± 1                   80 ± 40                   0.6 ± 0.1    8    5
   RyR1                 170 ± 30                500 ± 90                  0.5 ± 0.1    12   8
   RyR2                 100 ± 10                310 ± 40                  0.6 ± 0.1    12   4

Results are mean ± SD of at least four independent measurements.

###### 

Positive counterscreen results for the enzyme assays and nuclear receptor--based bioassays.

  Assay        Compound                                         IC~50~ or EC~50~ (nM)[a](#tfn3-ehp-117-1867){ref-type="table-fn"}   Use
  ------------ ------------------------------------------------ ------------------------------------------------------------------- -----------------
  sEH          Siduron                                          33 ± 3                                                              Herbicide
               TCC                                              13 ± 1                                                              Microbiocide
                                                                                                                                    
  CES1         Triclosan                                        210 ± 20                                                            Microbiocide
               TPP                                              43 ± 3                                                              Flame retardant
                                                                                                                                    
  CES2         Carbophenothion                                  34 ± 1                                                              Insecticide
               Triclosan                                        580 ± 30                                                            Microbiocide
               TPP                                              50 ± 2                                                              Flame retardant
                                                                                                                                    
  CES3         Carbophenothion                                  110 ± 15                                                            Insecticide
               Parathion                                        4.9 ± 0.4                                                           Insecticide
               Phosdrin                                         1.1 ± 0.1                                                           Insecticide
               Primiphos-ethyl                                  180 ± 20                                                            Insecticide
                                                                                                                                    
  PON2         Carbophenothion                                  110 ± 6                                                             Insecticide
               Tributyl phosphorotrithioite                     120 ± 10                                                            Herbicide
               TPP                                              85 ± 8                                                              Flame retardant
                                                                                                                                    
  CYP450 2C9   2-Butan-2-yl-4,6-dinitro-phenol                  1,900 ± 100                                                         Pesticide
               Chlorpyrifos                                     3,200 ± 200                                                         Insecticide
               Finasteride                                      1,500 ± 100                                                         Antiandrogen
               2-Methylheptyl-4,6-dinitrophenyl crotonate       120 ± 1                                                             Fungicide
               Pentachlorophenol                                850 ± 10                                                            Herbicide
               Pyrethrum                                        2,300 ±100                                                          Insecticide
               Triclosan                                        650 ± 40                                                            Microbiocide
                                                                                                                                    
  AhR          CPB                                              11,400                                                              Fungicide
               Dichlone                                         \> 10,000                                                           Fungicide
                                                                                                                                    
  ER           BPA                                              330                                                                 Plastic monomer
               *o*,*p-*DDD (dichlorodiphenyldichloroethane)     1,200                                                               Insecticide
               *o*,*p-*DDE (dichlorodiphenyldichloroethylene)   1,200                                                               Insecticide
               Endrin                                           13,000                                                              Pesticide
               Lindane                                          \> 50,000                                                           Insecticide

Values are IC~50~s for the enzyme-based assays (sEH to CYP450 2C9) and EC~50~s for the receptor-based assays (AhR and ER). Results are mean ± SD of at least three independent measurements.
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